PDGFRA and neoplasm: Lenvatinib is a small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) 1-3, fibroblast growth factor receptor (FGFR) 1-4, and platelet-derived growth factor receptor (PDGFR)-α, thereby inhibiting tumor angiogenesis, and has shown some efficacy against various solid tumors (13).